样式: 排序: IF: - GO 导出 标记为已读
-
Role of epicardial adipose tissue in diabetic cardiomyopathy through the lens of cardiovascular magnetic resonance imaging – a narrative review Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2024-03-11 Sindhoora Kotha, Sven Plein, John P. Greenwood, Eylem Levelt
Accumulating evidence suggests that ectopic/visceral adiposity may play a key role in the pathogenesis of nonischaemic cardiovascular diseases associated with type 2 diabetes. Epicardial adipose tissue (EAT) is a complex visceral fat depot, covering 80% of the cardiac surface with anatomical and functional contiguity to the myocardium and coronary arteries. EAT interacts with the biology of the underlying
-
The impact of socioeconomic factors, social determinants, and ethnicity on the utilization of glucose sensor technology among persons with diabetes mellitus: a narrative review Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2024-03-11 Riemer A. Been, Annel Lameijer, Reinold O. B. Gans, André P. van Beek, Andrew P. Kingsnorth, Pratik Choudhary, Peter R. van Dijk
Continuous glucose monitoring (CGM) usage has been shown to improve disease outcomes in people living with diabetes by facilitating better glycemic management. However, previous research has suggested that access to these devices can be influenced by nonmedical factors such as socioeconomic status and ethnicity. It is critical that equitable access to CGM devices is ensured as people from those groups
-
Epidemiology of gout – Global burden of disease research from 1990 to 2019 and future trend predictions Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2024-03-04 Tingfen Han, Wenli Chen, Xiasang Qiu, Weijie Wang
Background:Understanding the global burden of gout in the past and future can provide important references for optimizing prevention and control strategies in healthcare systems.Objectives:This study aimed to report variations in the global disease burden and risk factors of gout in 204 countries and territories from 1990 to 2019.Design:We conducted a retrospective analysis of gout based on the latest
-
Insulin therapy among diabetic patients in rural communities of Sub-Saharan Africa: a perspective review Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2024-02-20 Ritah Kiconco, Sylvia Achieng Lumumba, Charles Nkubi Bagenda, Raymond Atwine, Joseph Ndarubweine, Simon Peter Rugera
In this perspective review, we describe a brief background on the status quo of diabetes mellitus-related therapies and glycemic control among patients in rural communities in sub-Saharan Africa. The article discusses insulin therapy as well as the difficulties in obtaining insulin and oral hypoglycemic medications for diabetic patients living in sub-Saharan Africa. We wrap up our discussion with suggestions
-
Liver Biopsy Handling of Metabolic-Associated Fatty Liver Disease (MAFLD): the Children’s Hospital of Eastern Ontario grossing protocol Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2024-02-05 Consolato M. Sergi, Mohit Kehar, Carolina Jimenez-Rivera
Metabolic-(non-alcoholic) associated fatty liver disease (MAFLD/NAFLD) has increasingly become a worldwide epidemic. It has been suggested that renaming NAFLD to MAFLD is critical in identifying patients with advanced fibrosis and poor cardiovascular outcomes. There are concerns that the progression to non-alcoholic steatohepatitis (NASH) may become a constant drive in the future healthcare of children
-
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2024-01-28 Saleh Hadi Alharbi
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have emerged as promising therapeutic agents with potent anti-inflammatory properties and diverse clinical implications. This in-depth review article explores the mechanisms behind the anti-inflammatory actions of GLP-1RAs and assesses their prospective applicability in a wide range of disease scenarios. The current review establishes the significance
-
Therapeutic potential of adiponectin in prediabetes: strategies, challenges, and future directions Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2024-01-18 Mona Mohamed Ibrahim Abdalla
Adiponectin, an adipose-derived hormone, plays a pivotal role in glucose regulation and lipid metabolism, with a decrease in circulating adiponectin levels being linked to insulin resistance and prediabetes. This review examines the therapeutic potential of adiponectin in managing prediabetes, elucidating on multiple aspects including its role in glucose and lipid metabolism, influence on insulin sensitivity
-
Glycogen storage disease type III: a mixed-methods study to assess the burden of disease Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2024-01-08 Ayla Evins, Jill Mayhew, Tricia Cimms, Julie Whyte, Kathy Vong, Elizabeth Hribal, Christopher J. Evans, Andrew Grimm
Background:Glycogen storage disease type III (GSD III) is a rare inherited disorder that results from a glycogen debranching enzyme deficiency.Objectives:The purpose of this research was to collect data on the signs, symptoms, and impacts of GSD III from the perspective of adult patients and caregivers of individuals with GSD III.Design:Online survey and qualitative interviews.Methods:Following institutional
-
Zoledronic acid sequential to teriparatide may promote greater inhibition of bone resorption than zoledronic acid alone. Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-11-22 Sharon Giveon,Galia Zacay,Iris Vered,A Joseph Foldes,Liana Tripto-Shkolnik
Background Teriparatide (TPTD) should be followed by an antiresorptive to maximize bone mineral density gain and anti-fracture protection. Infrequent zoledronic acid (ZOL) administration has demonstrated effectiveness. The duration of ZOL effect following TPTD is unknown. Objective To evaluate the effect of ZOL on bone resorption marker in a post-TPTD versus ZOL-alone scenario in osteoporotic patients
-
Hypovitaminosis D masking hypercalcemia in primary hyperparathyroidism: case report. Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-11-17 Tamer Mohamed Elsherbiny
Hyperparathyroidism (HPTH) is the third most common endocrine disorder. Hypovitaminosis D affects up to 40% of the general population and about a third of hyperparathyroid patients. Such a combination may alter the classic presentation of HPTH. This report presents a premenopausal female with long history of osteoporosis, normocalcemia, and hypovitaminosis D who was initially diagnosed as secondary
-
Design and rationale for the SIB trial: a randomized parallel comparison of semaglutide versus placebo on intestinal barrier function in type 2 diabetes mellitus. Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-10-29 Steven Rella,Joseph Onyiah,Chelsea Baker,Vatsala Singh,Andrew Her,Neda Rasouli
Objective To describe the rationale and design of the SIB trial, an interventional clinical trial testing the hypothesis that subcutaneous (s.c.) once-weekly semaglutide can improve intestinal permeability and reduce systemic inflammation in participants with type 2 diabetes (T2D) and obesity. Methods SIB (NCT04979130) is an investigator-initiated, single-center randomized, double-blinded, placebo-controlled
-
Pheochromocytoma: a changing perspective and current concepts. Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-10-29 Andreas Kiriakopoulos,Periklis Giannakis,Evangelos Menenakos
This article aims to review current concepts in diagnosing and managing pheochromocytoma and paraganglioma (PPGL). Personalized genetic testing is vital, as 40-60% of tumors are linked to a known mutation. Tumor DNA should be sampled first. Next-generation sequencing is the best and most cost-effective choice and also helps with the expansion of current knowledge. Recent advancements have also led
-
Soluble tumor necrosis factor receptor type 1 predicts cardiorenal outcomes and better associated with distinct cardiovascular or renal outcomes than precedential renal or cardiovascular events in type 2 diabetes mellitus. Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-10-29 Li-Hsin Chang,Chia-Huei Chu,Chin-Chou Huang,Liang-Yu Lin
Background Inflammations are the crucial pathogenesis of chronic complications of type 2 diabetes mellitus (T2DM). Objectives The timeline of cardiovascular and renal complications of T2DM and whether soluble tumor necrosis factor receptor type 1 (sTNFR1) levels predict cardiorenal outcomes were still elusive. Design Prospectively observational study. Methods Chinese patients with T2DM were enrolled
-
Efficacy of zoledronate, denosumab or teriparatide in postmenopausal women with type 2 diabetes mellitus at high risk of fragility fractures: protocol of an open, blinded endpoint randomized controlled pilot trial. Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-10-21 Trupti Nagendra Prasad,Sanjay Kumar Bhadada,Veenu Singla,Neelam Aggarwal,Sant Ram,Uttam Chand Saini,Ashok Kumar,Rimesh Pal
Background People with type 2 diabetes (T2D) are at high risk of fragility fractures; however, there are no randomized controlled trials evaluating the efficacy of anti-osteoporosis drugs as a primary pre-specified endpoint in T2D. Objectives To compare the efficacy of anti-osteoporotic drugs in postmenopausal women with T2D. Design Prospective, randomized, open, blinded endpoint clinical pilot trial
-
Response to a low-energy meal replacement plan on glycometabolic profile and reverse cardiac remodelling in type 2 diabetes: a comparison between South Asians and White Europeans. Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-10-06 Lavanya Athithan,Gaurav S Gulsin,Joseph Henson,Loai Althagafi,Emma Redman,Stavroula Argyridou,Kelly S Parke,Jian Yeo,Thomas Yates,Kamlesh Khunti,Melanie J Davies,Gerry P McCann,Emer M Brady
Background South Asians (SA) constitute a quarter of the global population and are disproportionally affected by both type 2 diabetes (T2D) and heart failure. There remains limited data of the acceptability and efficacy of low-energy meal replacement plans to induce remission of T2D in SA. Objectives The objective of this exploratory secondary analysis of the DIASTOLIC study was to determine if there
-
Exploring the mechanism of metformin action in Alzheimer's disease and type 2 diabetes based on network pharmacology, molecular docking, and molecular dynamic simulation. Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-09-27 Xin Shi,Lingling Li,Zhiyao Liu,Fangqi Wang,Hailiang Huang
Background Metformin, which has been shown to be highly effective in treating type 2 diabetes (T2D), is also believed to be valuable for Alzheimer's disease (AD). Computer simulation techniques have emerged as an innovative approach to explore mechanisms. Objective To study the potential mechanism of metformin action in AD and T2D. Methods The chemical structure of metformin was obtained from PubChem
-
Association of hyponatremia with bone mineral density and fractures: a narrative review. Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-09-18 Ploutarchos Tzoulis,Maria P Yavropoulou
Recent studies suggest a possible association of hyponatremia with osteoporosis, falls and bone fractures. The objectives of this narrative review were to further explore this association and the related pathophysiological mechanisms and to suggest a practical approach to patients with osteoporosis or chronic hyponatremia in clinical practice. We conducted an extensive PubMed search until October 2022
-
Role of estrogen in the regulation of central and peripheral energy homeostasis: from a menopausal perspective. Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-09-15 Jing Zhu,Yier Zhou,Bihui Jin,Jing Shu
Estrogen plays a prominent role in regulating and coordinating energy homeostasis throughout the growth, development, reproduction, and aging of women. Estrogen receptors (ERs) are widely expressed in the brain and nearly all tissues of the body. Within the brain, central estrogen via ER regulates appetite and energy expenditure and maintains cell glucose metabolism, including glucose transport, aerobic
-
Prevalence and associated factors of hyperuricemia among Chinese patients with diabetes: a cross-sectional study. Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-09-13 Shiyi Sun,Lihong Chen,Dawei Chen,Yan Li,Guanjian Liu,Lin Ma,Jun Li,Fangwei Cao,Xingwu Ran
Background As a part of metabolic syndrome, hyperuricemia has a higher incidence in patients with diabetes than in the general population owing to various underlying factors. Objectives The objective of the present study was to investigate the prevalence of hyperuricemia among patients with diabetes and identify associated factors. Design A cross-sectional study. Methods Herein, we included patients
-
Immune cell infiltration in the pancreas of type 1, type 2 and type 3c diabetes. Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-07-25 Nicole Kattner
The different types of diabetes differ in disease pathogenesis but share the impairment or loss of β-cell function leading to chronic hyperglycaemia. While immune cells are present throughout the whole pancreas in normality, their number and activation is increased in diabetes. Different patterns and composition of inflammation could be observed in type 1, type 2 and type 3c diabetes. Immune cells
-
Is there a causal relationship between hypothyroidism and hyponatremia? Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-07-04 Julie Chen
Hyponatremia is one of the most common lab abnormalities seen in clinical practice. It has become widely accepted that hypothyroidism is a cause of euvolemic hyponatremia. The primary mechanism is thought to be due to impaired free water excretion and changes in sodium handling in the kidney. However, the clinical studies are conflicting and do not definitively confirm the association between hypothyroidism
-
Comparing ART outcomes in women with endometriosis after GnRH agonist versus GnRH antagonist ovarian stimulation: a systematic review. Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-07-04 Kevin K W Kuan,Sean Omoseni,Javier A Tello
Background Endometriosis is an oestrogen-dependent disease that can cause subfertility in women who may require assisted reproductive technology (ART) to achieve their pregnancy goals. Objectives The aim of this study was to compare ART outcomes in women with endometriosis following the long GnRH-agonist controlled ovarian stimulation (COS) protocol with those taking the GnRH-antagonist COS protocol
-
Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment. Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-06-29 Khary Edwards,Aleksandra Uruska,Anna Duda-Sobczak,Dorota Zozulinska-Ziolkiewicz,Ildiko Lingvay
Background Patients with type 1 diabetes mellitus (T1DM) may have suboptimal glucose control and are interested in the use of adjuvant therapies. Objectives To determine, from the patients' perspective, the reasons for initiation of glucagon-like peptide 1 receptor agonist (GLP-1RA) and/or sodium glucose cotransporter 2 inhibitor (SGLT2i) in treating T1DM; perceived benefits/side effects, reasons for
-
Implications of gender-affirming endocrine care for sports participation. Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-06-08 Ethan Moreland,Ada S Cheung,Danielle Hiam,Brendan J Nolan,Shanie Landen,Macsue Jacques,Nir Eynon,Patrice Jones
Many transgender (trans) individuals utilize gender-affirming hormone therapy (GAHT) to promote changes in secondary sex characteristics to affirm their gender. Participation rates of trans people in sport are exceedingly low, yet given high rates of depression and increased cardiovascular risk, the potential benefits of sports participation are great. In this review, we provide an overview of the
-
Fertility preservation options for transgender and nonbinary individuals. Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-06-06 Jensen Reckhow,Hakan Kula,Samir Babayev
Transgender and nonbinary individuals are historically underserved by healthcare systems. A crucial area for improvement is fertility preservation counseling and service delivery, as gender-affirming hormone therapy and gender-affirming surgery may negatively affect future fertility. The methods available for fertility preservation depend on the patient's pubertal status and utilization of gender-affirming
-
The bidirectional impacts of alcohol consumption and MAFLD for progressive fatty liver disease. Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-06-05 Anand V Kulkarni,Shiv Kumar Sarin
Nonalcoholic fatty liver disease (NAFLD), once considered a benign condition, has been associated with several cardiometabolic complications over the past two decades. The worldwide prevalence of NAFLD is as high as 30%. NAFLD requires the absence of a "significant alcohol intake." Conflicting reports have suggested that moderate alcohol consumption may be protective; therefore, the diagnosis of NAFLD
-
Fractures and dislocations of the foot and ankle in people with diabetes: a literature review. Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-06-03 Matthew J Johnson,Suganthi Kandasamy,Katherine M Raspovic,Kshitij Manchanda,George Tye Liu,Michael D VanPelt,Lawrence A Lavery,Dane K Wukich
Diabetes (DM) increases fracture risk, and bone quality depends on type diabetes type, duration, and other comorbidities. Diabetes is associated with a 32% increased relative risk (RR) of total fractures and 24% increased RR of ankle fractures compared with patients without DM. Type 2 DM is associated with a 37% increased RR of foot fractures compared with patients without DM. The incidence of ankle
-
RANKL inhibition: a new target of treating diabetes mellitus? Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-05-20 Baodi Xing,Jie Yu,Huabing Zhang,Yuxiu Li
Accumulating evidence demonstrates the link between glucose and bone metabolism. The receptor activator of nuclear factor-kB ligand (RANKL)/the receptor activator of NF-κB (RANK)/osteoprotegerin (OPG) axis is an essential signaling axis maintaining the balance between bone resorption and bone formation. In recent years, it has been found that RANKL and RANK are distributed not only in bone but also
-
Tolvaptan for the treatment of the syndrome of inappropriate antidiuresis (SIAD) Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-05-16 Ploutarchos Tzoulis, Gregory Kaltsas, Stephanie E. Baldeweg, Pierre-Marc Bouloux, Ashley B. Grossman
The syndrome of inappropriate antidiuresis (SIAD), the commonest cause of hyponatraemia, is associated with significant morbidity and mortality. Tolvaptan, an oral vasopressin V2-receptor antagonis...
-
Gender-affirming hormone therapy, mental health, and surgical considerations for aging transgender and gender diverse adults Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-04-19 Sean J. Iwamoto, Justine Defreyne, Christodoulos Kaoutzanis, Robert D. Davies, Kerrie L. Moreau, Micol S. Rothman
As the transgender and gender diverse (TGD) population ages, more transfeminine and transmasculine individuals present to clinic to initiate or continue their gender-affirming care at older ages. C...
-
Therapy for SIAD: what does the future hold? Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-04-19 Ploutarchos Tzoulis
-
Controversies in the management of active Charcot neuroarthropathy Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-04-17 Catherine Gooday, Wendy Hardeman, Fiona Poland, Jim Woodburn, Ketan Dhatariya
Charcot neuroarthropathy (CN) was first described over 150 years ago. Despite this there remains uncertanity around the factors that contribute to its development, and progression. This article wil...
-
A step-by-step guide for the diagnosis and management of hyponatraemia in patients with stroke Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-04-03 Fotios Barkas, Georgia Anastasiou, George Liamis, Haralampos Milionis
Hyponatraemia is common in patients with stroke and associated with adverse outcomes and increased mortality risk. The present review presents the underlying causes and provides a thorough algorith...
-
Gender-affirming endocrine care for youth with a nonbinary gender identity Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-03-30 Juanita K. Hodax, Sara DiVall
Nonbinary individuals, or those who identify outside of the traditional gender binary, are currently present in up to 9% of the general population of youth or up to 55% of gender-diverse youth. Des...
-
Should we undertake surveillance for HCC in patients with MAFLD? Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-03-28 Blanca Norero, Jean-François Dufour
Over the last decade, metabolic-associated fatty liver disease (MAFLD) has become an important public health issue worldwide. In many countries, MAFLD has become the most common cause of chronic li...
-
Non-pharmacological management options for MAFLD: a practical guide Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-03-21 José Tadeu Stefano, Sebastião Mauro Bezerra Duarte, Renato Gama Ribeiro Leite Altikes, Claudia P. Oliveira
Lifestyle changes should be the main basis for any treatment for metabolic dysfunction–associated fatty liver disease (MAFLD), aiming to increase energy expenditure, reduce energy intake and improv...
-
Fatty liver disease in children (MAFLD/PeFLD Type 2): unique classification considerations and challenges Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-03-22 Robert Hegarty, Eirini Kyrana, Emer Fitzpatrick, Anil Dhawan
In children, fatty liver disease is a group of disorders that often overlaps with inherited metabolic disorders (IMDs), which requires prompt diagnosis and specific management. Metabolic dysfunctio...
-
The role of supporting and disruptive mechanisms of FT3 homeostasis in regulating the hypothalamic–pituitary–thyroid axis Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-03-14 Rudolf Hoermann, Mark J. Pekker, John E. M. Midgley, Johannes W. Dietrich
Background:Thyroid hormones are controlled by the hypothalamic–pituitary–thyroid (HPT) axis through a complex network of regulatory loops, involving the hormones TRH, TSH, FT4, and FT3. The relatio...
-
Tackling diabetic foot: limb salvage during the COVID-19 pandemic Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-03-03 Brian M. Schmidt, Laura Shin
Purpose:Lower extremity amputation resulting from diabetic foot ulcer, with neuropathic and/or ischemic etiologies, remains a devastating and costly complication of diabetes mellitus. This study ev...
-
Immune checkpoint inhibitors: friend or foe for osteoporosis. Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-03-01 Jun Tang
-
MAFLD: a multisystem disease Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-01-28 Rosaria Maria Pipitone, Carlo Ciccioli, Giuseppe Infantino, Claudia La Mantia, Stefanie Parisi, Adele Tulone, Grazia Pennisi, Stefania Grimaudo, Salvatore Petta
Nonalcoholic fatty liver disease (NAFLD), affecting about 25% of general population and more than 50% of dysmetabolic patients, is an emerging cause of chronic liver disease and its complications. ...
-
Screening for MAFLD: who, when and how? Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-01-21 Shreya C. Pal, Nahum Méndez-Sánchez
Metabolic-associated fatty liver disease (MAFLD) is a highly prevalent disease with increasing prevalence worldwide. Currently, no universal screening methods have been standardized, even when this...
-
Influence of the occurrence and duration of partial remission on short-term metabolic control in type 1 diabetes: the DIABHONEY pediatric study Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-01-21 Laure Boutsen, Elise Costenoble, Olivier Pollé, Kezban Erdem, Céline Bugli, Philippe A. Lysy
Objective:To evaluate the residual effect of partial remission (PR) on immediate post-PR glycemic control according to its occurrence and duration in a cohort of children with type 1 diabetes melli...
-
Differences in adherence to using removable cast walker treatment during daytime and nighttime weight-bearing activities in people with diabetes-related foot ulcers Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2023-01-10 Anas Ababneh, Kathleen Finlayson, Helen Edwards, Jaap J. van Netten, Peter A. Lazzarini
Aims:Patients’ adherence to using knee-high offloading treatment is critical to effective healing of diabetes-related foot ulcers (DFUs). Previous studies have found that patients generally have lo...
-
Effect of sodium-glucose cotransporter-2 inhibitors on patients with essential hypertension and pre-hypertension: a meta-analysis Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2022-12-10 Bangjiaxin Ren, Ming Chen
Background:Sodium-glucose cotransporter-2 (SGLT2) inhibitors are novel, hypoglycemic drugs exhibiting cardiovascular protective activities. If SGLT2 inhibitors can be successfully used as antihyper...
-
Emerging pharmacological treatment options for MAFLD Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2022-12-10 Ángela Rojas, Carmen Lara-Romero, Rocío Muñoz-Hernández, Sheila Gato, Javier Ampuero, Manuel Romero-Gómez
Metabolic dysfunction–associated fatty liver disease (MAFLD) prevalence and incidence is rising globally. It is associated with metabolic comorbidities, obesity, overweight, type 2 diabetes mellitu...
-
A case of pheochromocytoma associated with liver abscess and intestinal pseudo-obstruction Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2022-12-10 Mikiko Okazaki-Hada, Izumi Fukuda, Ryuta Nagaoka, Mototsugu Nagao, Takehito Igarashi, Shunsuke Kobayashi, Takeshi Oba, Yuji Yamaguchi, Tomoko Nagamine, Iwao Sugitani, Hitoshi Sugihara
Pheochromocytomas can present with various symptoms. Nonspecific manifestations of pheochromocytoma include intestinal pseudo-obstruction and weight loss. Here, we present a case of pheochromocytom...
-
Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2022-12-10 Eda Kaya, Yusuf Yilmaz
Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is the most common chronic liver disease worldwide – with an estimated global prevalence of 37%. Different from nonalcoholic fatty liv...
-
Non-invasive assessment of metabolic dysfunction–associated fatty liver disease Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2022-12-10 C. Vikneshwaran Chandra Kumar, Ruben Skantha, Wah-Kheong Chan
Non-alcoholic fatty liver disease (NAFLD) affects an estimated one-quarter of the global adult population and has become one of the leading causes of end-stage liver disease and hepatocellular carc...
-
Potential immunological effects of gender-affirming hormone therapy in transgender people – an unexplored area of research Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2022-12-10 Alice A. White, Ashleigh Lin, Xander Bickendorf, Blake S. Cavve, Julia K. Moore, Aris Siafarikas, Deborah H. Strickland, Jonatan Leffler
There are well-described sex-based differences in how the immune system operates. In particular, cisgender (cis) females have a more easily activated immune system; associated with an increased pre...
-
MAFLD: what 2 years of the redefinition of fatty liver disease has taught us Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2022-11-22 Felix Grabherr, Christoph Grander, Maria Effenberger, Julian Schwärzler, Herbert Tilg
Metabolic dysfunction–associated fatty liver disease (MAFLD) has appeared as the leading liver disease worldwide. Whereas the terminology nonalcoholic fatty liver disease (NAFLD) mainly reflected a...
-
Characterizing palliative care needs in people with or at risk of developing diabetic foot ulcers Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2022-11-14 Liliane Mendonça, Bárbara Antunes, Joana Rigor, Daniela Martins-Mendes, Matilde Monteiro-Soares
Aims:Diabetic foot ulcers (DFUs) have a significant impact on a patient’s quality of life and life expectancy, with mortality rates comparable with malignant diseases. However, there is a lack of d...
-
Hyponatraemia in patients on immune checkpoint inhibitors. Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2022-11-14 Stavroula A Paschou,Evanthia Kassi,Theodora Psaltopoulou
-
Update on genetics and epigenetics in metabolic associated fatty liver disease Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2022-10-28 Xiaopeng Zhu, Mingfeng Xia, Xin Gao
Nonalcoholic fatty liver disease (NAFLD) is becoming the most frequent chronic liver disease worldwide. Metabolic (dysfunction) associated fatty liver disease (MAFLD) is suggested to replace the no...
-
Menopause, androgens, and cardiovascular ageing: a narrative review Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2022-10-28 Eleni Armeni, Irene Lambrinoudaki
Cardiovascular disease is the leading cause of death worldwide; however, women tend to be less affected than men during their reproductive years. The female cardiovascular risk increases significan...
-
Impact of metformin on the clinical and metabolic parameters of women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2022-10-07 Mohammed Altigani Abdalla, Najeeb Shah, Harshal Deshmukh, Amirhossein Sahebkar, Linda Östlundh, Rami H. Al-Rifai, Stephen L. Atkin, Thozhukat Sathyapalan
Context:Polycystic ovary syndrome (PCOS) is one of the commonest endocrine disorders affecting women of reproductive age, and metformin is a widely used medication in managing this condition.Aim:To...
-
Metabolic benefits of changing sedentary lifestyles in nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2022-09-16 Qianqian Ma, Junzhao Ye, Congxiang Shao, Yansong Lin, Tingfeng Wu, Bihui Zhong
This study seeks to evaluate the effects of a reversal of sedentary lifestyles on the improvement of metabolic profiles in patients with NAFLD. The PubMed, Cochrane Library, Web of Science, and CNK...
-
Association between the metabolic profile of serum fatty acids and diabetic nephropathy: a study conducted in northeastern China Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2022-09-16 Yazhuo Liu, Yingying Li, Hui Shen, Yike Li, Yanbing Xu, Mi Zhou, Xinghai Xia, Binyin Shi
Background and purpose:With the progressive increase in the prevalence of type 2 diabetes mellitus (T2DM), diabetic nephropathy (DN) – one of the most common chronic microvascular complications – h...
-
The prevalence and associated predictors for Bethesda III–VI for reporting thyroid cytopathology in Royal Commission Hospital, Kingdom of Saudi Arabia Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2022-09-12 Hussain Alyousif, Ishag Adam, Naser A. Alamin, Mona A. Sid Ahmed, Ayat Al Saeed, Abdulmuhsen Hussein Hassoni, Imad R. Musa
Background:Thyroid cancer is increasing globally and is currently the most prevalent endocrine malignancy. Recent data show an increase in the incidence of thyroid cancer in the Kingdom of Saudi Ar...
-
Ankle brachial indices and anaerobes: is peripheral arterial disease associated with anaerobic bacteria in diabetic foot ulcers? Ther. Adva. Endocrinol. Metab. (IF 3.8) Pub Date : 2022-08-23 J.Z. Alex Cheong, Jessica M. Irvine, Shane Roesemann, Anna Nora, Courtney E. Morgan, Christopher Daniele, Lindsay R. Kalan, Meghan B. Brennan
Background:Lower extremity amputations from diabetic foot ulcers (DFUs) are rebounding, and new biomarkers that predict wound healing are urgently needed. Anaerobic bacteria have been associated wi...